- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05592028
High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism
Bilateral Transcranial Magnetic Resonance-guided Focused Ultrasound Pallidothalamic Tractotomy for Patients With X-linked Dystonia-parkinsonism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To determine the outcomes of MRgFUS pallidothalamic tractotomy on adult XDP patients at the Philippine General Hospital.
This is a prospective study that aims to determine the outcomes of MRgFUS pallidothalamic tractotomy (both unilateral and bilateral) on adult XDP patients at the Philippine General Hospital.
No sample size will be determined a priori. The study will be conducted over a period of five years, and all eligible patients may be invited to join the study during this period.
The procedure will be performed inside the MRI suite, using a 1.5 Tesla MRI system (GE Optima MR450, USA) and the ExAblate Neuro device (InSightec, Haifa, Israel) to deliver the focused ultrasound. The patient's head will be shaved and immobilized using a stereotactic frame under local anesthesia. An elastic diaphragm will be attached to the patient's head and connected to the ultrasound transducer,8 and the patient will be positioned inside the bore of the MRI. A reference MRI scan will be performed to position the transducer to the target, after which the MRI images (T1-weighted axial and T2-weighted axial/coronal MRI at 1 mm slices) will be fused to the preoperative CT scan for the skull-correction algorithm.8 Stereotactic treatment planning will then be performed to target the pallidothalamic tract. It is usually located at the midcommisural line (0 to 1.0 mm posterior) in the anterior-posterior direction, 8-10 mm lateral to the intercommisural line in the mediolateral direction, 0-1.5 mm inferior to the intercommisural line in the dorsoventral direction, and 6.5-7.5 mm to the thalamo-ventricular border.7 The lesion will be made 3 mm lateral to the mamillo-thalamic tract and superior and medial to the medial subthalamic nucleus.9,11,12 Once the target is set, a series of low-power sonications producing temperatures between 40-45oC and lasting 10-20 seconds will be performed.8 Clinical assessment for tremor suppression and treatment side effects will be made after each sonication,8 and definitive non-reversible thermal ablation will be performed only at the setting wherein the patient experiences tremor reduction or suppression with no adverse effects.9 The final sonication temperature usually ranges between 55-63oC.8 After the treatment, the stereotactic frame will be removed and the patient will be monitored in the hospital overnight.
The patients will be assessed within 24 hours of treatment then asked to follow up with the movement disorder neurologist (RDJ) at 2 weeks, 3 months, 6 months, 9 months, and 12 months post-treatment through a clinic visit. Video recording will be taken on initial visit and at each follow up visit. Another blinded assessor will score the videos of the patients. The outcome will be assessed using the XDP-Movement Disorder Society of the Philippines (XDP-MDSP) Scale at each visit, and comparing it to the pre-treatment baseline, as well as using the XDP Clinical and Functional Staging. The pre- and post-treatment BFMDRS and UPDRS scores will also be obtained.
For bilateral MRgFUS tractotomy, the contralateral lesion will be done at least 6 months after the first procedure, provided that there are no serious adverse effects from the first PTT lesioning.
Demographic, clinical, treatment-related, and outcome data of all study patients will be collected prospectively by the investigators throughout the duration of the study.
Study Type
Expanded Access Type
- Individual Patients
- Intermediate-size Population
- Treatment IND/Protocol
Contacts and Locations
Study Contact
- Name: Roland Dominic G Jamora, MD, PhD
- Phone Number: +63 2 85242338
- Email: rgjamora@up.edu.ph
Study Contact Backup
- Name: Kathleen Joy O Khu, MD
- Phone Number: +63 2 85242338
- Email: kokhu@up.edu.ph
Study Locations
-
-
-
Manila, Philippines, 1000
- Available
- Philippine General Hospital
-
Contact:
- Roland Dominic G Jamora, MD, PhD
- Phone Number: +63 2 85242338
- Email: rgjamora@up.edu.ph
-
Contact:
- Kathleen Joy O Khu, MD
- Phone Number: +63 2 85242338
- Email: kokhu@up.edu.ph
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years old and above
- have been diagnosed with XDP and confirmed by genetic testing
- have a skull density ratio (SDR) of >/= 0.35 on CT scan
- have psychiatric and medical clearance
- have passed the neurocognitive test
- have undergone MRgFUS pallidothalamic tractomy, either unilateral or bilateral,
Exclusion Criteria:
- patients aged less than 18 years old
- patients who have movement disorders other than XDP
- patients with abnormal neuroimaging findings that would preclude MRgFUS lesioning
- Skull SDR < 0.35
- patients with medical contraindications
- patients who did not fulfill the inclusion criteria
Study Plan
How is the study designed?
Collaborators and Investigators
Investigators
- Principal Investigator: Roland Dominic G Jamora, MD, PhD, Department of Neurosciences, University of the Philippines Manila
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DoN-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-Linked Dystonia Parkinsonism
-
Sunshine Care FoundationMassachusetts General Hospital; Jose R. Reyes Memorial Medical CenterCompletedX-Linked Dystonia ParkinsonismPhilippines
-
State University of New York at BuffaloNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingDystonia | ParkinsonismUnited States
-
National Eye Institute (NEI)Active, not recruiting
-
Institute of Child HealthUniversity College, London; Great Ormond Street Hospital for Children NHS Foundation...RecruitingAlternating Hemiplegia of Childhood | ATP1A3-related Disease | Rapid Onset Dystonia Parkinsonism | CAPOSUnited Kingdom
-
National Eye Institute (NEI)CompletedRetinoschisis | X-LinkedUnited States
-
University of Alabama at BirminghamMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson Disease | Dystonia-Parkinsonism, Adult-OnsetUnited States
-
West China HospitalRecruiting
-
University of MiamiJackson Health SystemNo longer available
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingX-linked Myotubular Myopathy | Centronuclear Myopathy | Myotubular Myopathy | Myotubular Myopathy 1 | Myotubular (Centronuclear) Myopathy | Centronuclear Myopathy, X-LinkedUnited Kingdom
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.; Foundation Fighting BlindnessCompletedRetinitis Pigmentosa | X-linked Genetic DiseasesUnited States
Clinical Trials on transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy
-
Yonsei UniversityCompletedLevodopa Induced Dyskinesia in Patients With Parkinson's DiseaseKorea, Republic of
-
Yonsei UniversityUnknown
-
Imperial College LondonInSightecWithdrawnPregnancy | Uterine FibroidsUnited Kingdom
-
Rambam Health Care CampusUnknownAmputation | Phantom Limb Pain | Residual LimbsIsrael
-
Taipei Medical University Shuang Ho HospitalUnknownMagnetic Resonance Guided Interventional ProceduresTaiwan
-
UMC UtrechtTerminated
-
University Health Network, TorontoCanadian Cancer Society (CCS); Brain CanadaRecruitingBrain Neoplasms | Liquid BiopsyCanada
-
University Health Network, TorontoUniversité de SherbrookeRecruiting
-
Ohio State UniversityNot yet recruitingAnxiety | Medication-refractory Focal-onset EpilepsyUnited States
-
InSightecRecruitingGlioblastoma | Glioma, MalignantItaly, Spain